Chinese Herbal Medicines for Prostate Cancer Therapy: From Experimental Research to Clinical Practice

Overview

Journal Chin Herb Med

Publisher Elsevier

Date 2023 Dec 14

PMID 38094009

Authors

Fanming Kong

Chaoran Wang

Jing Zhang

Xiaoqun Wang

Binxu Sun

Xian Xiao

Haojian Zhang

Yanqi Song

Yingjie Jia

Affiliations

Soon will be listed here.

Abstract

Prostate cancer remains the second most common malignancy in men worldwide, is a global health issue, and poses a huge health burden. Precision medicine provides more treatment options for prostate cancer patients, but its popularity, drug resistance, and adverse reactions still need to be focused on. Chinese herbal medicines (CHMs) have been widely accepted as an alternative therapy for cancer, with the advantages of multiple targets, multiple pathways, and low toxicity. We searched the experimental research and clinical practice of CHMs for prostate cancer treatment published in PubMed, Embase, and Web of Science in the last five years. We found five CHM formulas and six single CHM extracts as well as 12 CHM-derived compounds, which showed induction of apoptosis, autophagy, and cell cycle arrest, suppression of angiogenesis, proliferation, and migration of prostate cancer cells, reversal of drug resistance, and enhancement of anti-tumor immunity. The mechanisms of action include the PI3K/Akt/mTOR, AR, EGFR and Wnt/-catenin signaling pathways, which are commonly implicated in the development of prostate cancer. We also summarized the advantages of CHMs in patients with hormone-sensitive and castration-resistant prostate cancer and provided ideas for their further experimental design and application.

Citing Articles

Phytochemical synergies in BK002: advanced molecular docking insights for targeted prostate cancer therapy.

Park M, Choi J, Maharub Hossain Fahim M, Asevedo E, Nurkolis F, Ribeiro R Front Pharmacol. 2025; 16:1504618.

PMID: 40034825 PMC: 11872924. DOI: 10.3389/fphar.2025.1504618.

Enhancing chemoimmunotherapy for colorectal cancer with paclitaxel and alantolactone via CD44-Targeted nanoparticles: A STAT3 signaling pathway modulation approach.

Wu F, An X, Li S, Qiu C, Zhu Y, Ye Z Asian J Pharm Sci. 2025; 20(1):100993.

PMID: 39917727 PMC: 11795048. DOI: 10.1016/j.ajps.2024.100993.

Mechanisms of T-cell Depletion in Tumors and Advances in Clinical Research.

Su X, Zhang M, Zhu H, Cai J, Wang Z, Xu Y Biol Proced Online. 2025; 27(1):5.

PMID: 39905296 PMC: 11792740. DOI: 10.1186/s12575-025-00265-6.

Antiproliferative effects of resorcylic acid lactones from the Beibu Gulf coral-derived fungus GXIMD 02512 on prostate cancer cells.

Wang J, Lu H, Fang W, Lin M, Feng Y, Qi X RSC Adv. 2024; 14(52):38697-38705.

PMID: 39654917 PMC: 11626384. DOI: 10.1039/d4ra06292b.

M1 macrophage-membrane-cloaked paclitaxel/β-elemene nanoparticles targeting cervical cancer for enhanced therapy.

Wang Y, Wang J, Huang C, Ding Y, Lv L, Zhu Y Int J Pharm X. 2024; 8:100276.

PMID: 39263001 PMC: 11387591. DOI: 10.1016/j.ijpx.2024.100276.

References

Rashid H, Xu Y, Muhammad Y, Wang L, Jiang J . Research advances on anticancer activities of matrine and its derivatives: An updated overview. Eur J Med Chem. 2018; 161:205-238. DOI: 10.1016/j.ejmech.2018.10.037. View

Al-Rabia M, Alhakamy N, Rizg W, Alghaith A, Ahmed O, Fahmy U . Boosting curcumin activity against human prostatic cancer PC3 cells by utilizing scorpion venom conjugated phytosomes as promising functionalized nanovesicles. Drug Deliv. 2022; 29(1):807-820. PMC: 8920388. DOI: 10.1080/10717544.2022.2048133. View

Huang H, Wang Q, Du T, Lin C, Lai Y, Zhu D . Matrine inhibits the progression of prostate cancer by promoting expression of GADD45B. Prostate. 2018; 78(5):327-335. DOI: 10.1002/pros.23469. View

Gong X, Wang J, Yu X, Liu R, Chu L, Li Y . Assessment of the efficacy of Chinese patent medicine on treating pain caused by prostate cancer: A protocol for systematic review and meta analysis. Medicine (Baltimore). 2019; 98(51):e17820. PMC: 6940137. DOI: 10.1097/MD.0000000000017820. View

Rutz J, Benchellal A, Kassabra W, Maxeiner S, Bernd A, Kippenberger S . Growth, Proliferation and Metastasis of Prostate Cancer Cells Is Blocked by Low-Dose Curcumin in Combination with Light Irradiation. Int J Mol Sci. 2021; 22(18). PMC: 8469895. DOI: 10.3390/ijms22189966. View

Han W, Shi Y, Su J, Zhao Z, Wang X, Li J . Virtual Screening and Bioactivity Evaluation of Novel Androgen Receptor Antagonists From Anti-PCa Traditional Chinese Medicine Prescriptions. Front Chem. 2020; 8:582861. PMC: 7528374. DOI: 10.3389/fchem.2020.582861. View

Hnit S, Yao M, Xie C, Ge G, Bi L, Jin S . Transcriptional regulation of G/M regulatory proteins and perturbation of G/M Cell cycle transition by a traditional Chinese medicine recipe. J Ethnopharmacol. 2020; 251:112526. DOI: 10.1016/j.jep.2019.112526. View

Liu D, Li Z, Chen Q, Zhao J, Su Y, Xiang S . [Yishen Tonglong Decoction inhibits the epithelial-mesenchymal transition and Ras/ERK signaling pathway in human prostate cancer DU-145 cells]. Zhonghua Nan Ke Xue. 2021; 27(10):909-916. View

Ossikbayeva S, Khanin M, Sharoni Y, Trachtenberg A, Tuleukhanov S, Sensenig R . Curcumin and Carnosic Acid Cooperate to Inhibit Proliferation and Alter Mitochondrial Function of Metastatic Prostate Cancer Cells. Antioxidants (Basel). 2021; 10(10). PMC: 8533243. DOI: 10.3390/antiox10101591. View

10.

Kirby M, Hirst C, Crawford E . Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011; 65(11):1180-92. DOI: 10.1111/j.1742-1241.2011.02799.x. View

11.

Ma F, Xue P, Wang Y, Wang Y, Xue S . [Research progress of serum pharmacochemistry of traditional Chinese medicine]. Zhongguo Zhong Yao Za Zhi. 2017; 42(7):1265-1270. DOI: 10.19540/j.cnki.cjcmm.20170224.010. View

12.

Pan-On S, Dilokthornsakul P, Tiyaboonchai W . Trends in advanced oral drug delivery system for curcumin: A systematic review. J Control Release. 2022; 348:335-345. DOI: 10.1016/j.jconrel.2022.05.048. View

13.

Hashemzaei M, Delarami Far A, Yari A, Entezari Heravi R, Tabrizian K, Taghdisi S . Anticancer and apoptosis‑inducing effects of quercetin in vitro and in vivo. Oncol Rep. 2017; 38(2):819-828. PMC: 5561933. DOI: 10.3892/or.2017.5766. View

14.

Qi F, Zhao L, Zhou A, Zhang B, Li A, Wang Z . The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends. 2015; 9(1):16-34. DOI: 10.5582/bst.2015.01019. View

15.

Wang Z, Wang X, Zhang D, Hu Y, Li S . [Traditional Chinese medicine network pharmacology: development in new era under guidance of network pharmacology evaluation method guidance]. Zhongguo Zhong Yao Za Zhi. 2022; 47(1):7-17. DOI: 10.19540/j.cnki.cjcmm.20210914.702. View

16.

Luo Y, Wang C, Sawadogo R, Tan T, Yuan C . Effects of Herbal Medicines on Pain Management. Am J Chin Med. 2020; 48(1):1-16. DOI: 10.1142/S0192415X20500019. View

17.

Wei C, Jing J, Zhang Y, Fang L . Wogonoside Inhibits Prostate Cancer Cell Growth and Metastasis via Regulating Wnt/β-Catenin Pathway and Epithelial-Mesenchymal Transition. Pharmacology. 2019; 104(5-6):312-319. DOI: 10.1159/000502400. View

18.

Sun S, Gong F, Liu P, Miao Q . Metformin combined with quercetin synergistically repressed prostate cancer cells via inhibition of VEGF/PI3K/Akt signaling pathway. Gene. 2018; 664:50-57. DOI: 10.1016/j.gene.2018.04.045. View

19.

Zhang X, Huang J, Yu C, Xiang L, Li L, Shi D . Quercetin Enhanced Paclitaxel Therapeutic Effects Towards PC-3 Prostate Cancer Through ER Stress Induction and ROS Production. Onco Targets Ther. 2020; 13:513-523. PMC: 6970612. DOI: 10.2147/OTT.S228453. View

20.

Zhang B, Zhang J . [Twenty years' review and prospect of modernization research on traditional Chinese medicine]. Zhongguo Zhong Yao Za Zhi. 2016; 40(17):3331-4. View